Abstract:Lissencephaly is a developmental cortical malformation characterized by reduced to absent gyri and a disorganized cortex, often leading to severe impairments in affected individuals and a reduced life expectancy. Heterozygous mutations in the gene, encoding a regulator of the microtubule motor dynein, cause lissencephaly with different clinical severities. While the clinical disease spectrum correlates with the degree of lissencephaly, location and type of mutation may not. We leveraged forebrain-type organoids from LIS1-lissencephaly patients, diagnosed with mild, moderate or severe lissencephaly to investigate, in a cytoarchitecture and multi-omics approach, how the severity degree in patients might relate to specific mutations in the gene. We questioned which processes during cortical development might be differentially affected by severity grade, and whether they could be pharmacologically targeted. We found alterations in neurodevelopment often with a severity- dependent gradient. Specifically, we identified alterations of the cytoarchitecture, progenitor cell homeostasis and neurogenesis. Particularly important disease-linked molecular mechanisms were microtubule destabilization, WNT-signaling, and perturbed cadherin- and unfolded protein-binding. Some mechanisms exhibited a severity-dependent gradient, or were specific to a severe grade. We present strategies to reverse phenotypic changes in LIS1- patient organoids, and an approach with therapeutic potential. Thus, we show that different LIS1-severity grades can be recapitulated , that there is a direct link between the phenotype and genotype, that organoid-based disease modeling can identify molecular underpinnings of malformations of cortical development and that organoids provide a valid platform to develop and test therapeutic strategies.

Alteration of the LIS1 gene in Japanese patients with isolated lissencephaly sequence or Miller-Dieker syndrome

Genetic alteration of the DCX gene in Japanese patients with subcortical laminar heterotopia or isolated lissencephaly sequence

Molecular cloning of the chromosomal breakpoint in the LIS1 gene of a patient with isolated lissencephaly and balanced t(8;17)

Fluorescence in situ hybridization analysis with LIS1 specific probes reveals a high deletion mutation rate in isolated lissencephaly sequence

Causal heterogeneity in isolated lissencephaly

Characterization of intragenic tandem duplication in the PAFAH1B1 gene leading to isolated lissencephaly sequence

Isolated Lissencephaly: Report of Four Patients From Two Unrelated Families

Increased LIS1 expression affects human and mouse brain development (Reprinted from Nature Gentics, vol 41, pgs 168-177, 2008)

Increased LIS1 Expression Affects Human and Mouse Brain Development

Exploring unsolved cases of lissencephaly spectrum: integrating exome and genome sequencing for higher diagnostic yield

Multiple dose-dependent effects of Lis1 on cerebral cortical development

Novel compound heterozygous GPR56 gene mutation in a twin with lissencephaly: A case report

A Case of Megalencephalic Leukoencephalopathy with Subcortical Cysts Type 1 Was Identified with a Novel Compound Heterozygous Alteration (c.135delc; C.423+2dupt) in China

Lissencephaly and band heterotopia: LIS1, TUBA1A, and DCX mutations in Hungary

Target Capture/Next-Generation Sequencing for Nonsyndromic Cleft Lip and Palate in the Japanese Population

Identification of Novel MLC1 Mutations in Chinese Patients with Megalencephalic Leukoencephalopathy with Subcortical Cysts (MLC)

A variant suggests a phenotypic relation with lissencephaly in humans

Multiplex Consanguineous Family Highlights CLASP1 as a Candidate Gene for Lissencephaly

L1 Syndrome Prenatal Diagnosis Supplemented by Functional Analysis of One L1CAM Gene Missense Variant

[Molecular genetics of lissencephaly and microcephaly]

Unraveling LIS1-Lissencephaly: Insights from Cerebral Organoids Suggest Severity- Dependent Genotype-Phenotype Correlations, Molecular Mechanisms and Therapeutic Strategies